Report Id: SNS/HC/1014 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Blood Testing Market Size was valued at USD 2.33 billion in 2021 and is expected to reach USD 4.03 billion by 2028, and grow at a CAGR of 8.1% over the forecast period 2022-2028.
Blood testing is a lab test procedure that determines the state of a patient's health by taking a blood sample from the patient's body with syringes or a fingertip prick. Blood tests can be used to determine how well organs are working. These tests are cheaply priced and are typically performed in clinics and hospitals as a vital checkup for recognizing any mild to severe illnesses, which has an impact on the blood testing market's growth. In recent years, the blood testing industry has experienced tremendous expansion. The influence of the world's aging population is driving the market's expansion. The number of strategic acquisitions and mergers in the global market has recently increased dramatically, causing industry leaders' product portfolios to expand and their marketing power to strengthen.
Additionally, factors such as the expanding use of blood testing in other diagnostic areas and the rise in the occurrences of various diseases like bacterial and viral allergic disorders, cancer, Human Immunodeficiency Virus (HIV) infection, thyroids, genetic disorders, and hepatitis are expected to boost market efficiency over the forecasted period. On the other side, the market's growth will be hampered in the coming years by a lack of awareness of recent advancements, regulatory approval processes, and the high cost of automated blood testing.
Rise in the number of blood donation
Blood screening devices are expensive.
IMPACT OF COVID-19:
The beginning of the COVID-19 pandemic has changed clinical consideration conveyance all over the planet. Many hospitals and departments have been re-profiled for treating COVID-19 patients due to increased pressure from the rising rate of COVID-19 hospitalizations. The COVID-19 epidemic prompted worldwide curfews and lockdowns, halting blood donations, canceling collecting drives, and reducing demand for given blood. It modestly affects the market for blood screening. As curfews and social confinement become less severe, a request is probably going to rise, bringing about a market shortage. Governments around the world are, though, taking steps to increase donations during the anticipated period in order to meet the unexpected surge in need following the shutdown.
Furthermore, the number of cancer patients is rising, increasing the demand for donated blood. Blood and platelets are required for cancer patients' treatment (chemotherapy), blood replacement (for blood cancer patients), and surgery.
By Product and Service
Reagents and kits, devices, and software and services make up the blood screening market. In 2021 reagents and kits held the biggest part of the blood screening market, owing to an increase in blood transfusion operations, which resulted in increased consumption and repeated usage of reagents and kits in blood screening processes.
The nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), fast tests, western blot assays, and next-generation sequencing (NGS) segments of the blood screening business. The nucleic acid test (NAT) category will account for the majority of the blood screening market by 2020. Reasons like the expanding volume of blood donations and the increasing acceptance of NAT technology due to its higher sensitivity than other blood screening technologies.
The blood screening industry is divided into two categories: blood banks and hospitals. The blood banks category held the highest share of the blood screening market in 2021. The increasing number of organ transplant surgeries is propelling this market forward.
Some of the major key players are as follows: Abbott, Bio-Rad Laboratories, Inc., Trinity Biotech Plc, F. Hoffmann-La Roche AG, BioMerieux SA, Biomerica, Inc., Quest Diagnostics, Danaher Corporation, Siemens Healthineers, Becton, Dickinson, and Company.
KEY MARKET SEGMENT:
By Product and Service
1. Reagents & Kits
3. Software & Services
1. Nucleic Acid Test
3. Rapid Tests
4. Next-generation Sequencing
5. Western Blot Assays
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five key regions that make up the worldwide blood screening market. North America held the highest share of the blood screening market in 2021. The rise of the North American blood screening market can be due to rising healthcare spending, rising chronic disease prevalence, and the highly developed healthcare systems in the United States and Canada.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 2.33 Billion|
|Market Size by 2028||US$ 4.03 Billion|
|CAGR||CAGR of 8.1% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product and Service (Reagents & Kits (NAT Reagents & Kits, Other Reagents & Kits, ELISA Reagents & Kits)
• By Instruments (Outright Purchase, Rental Purchase), Software & Services)
• By Technology (Nucleic Acid Test, ELISA, Rapid Tests, Next-generation Sequencing, Western Blot Assays)
• By End User (Hospitals, Blood Banks)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Abbott, Bio-Rad Laboratories, Inc., Trinity Biotech Plc, F. Hoffmann-La Roche AG, BioMerieux SA, Biomerica, Inc., Quest Diagnostics, Danaher Corporation, Siemens Healthineers, Becton, Dickinson, and Company.|
|DRIVING FACTORS||• Rise in the number of blood donation|
|Restraints||• Technology alternatives|
Frequently Asked Questions (FAQ) :
The blood Testing market is expected to grow at a CAGR of 8.1% over the forecast period 2022-2028.
Technology alternatives are the restraints of the Blood Testing market.
The blood Testing Market is divided into two segments and they are By Product and Service, By Technology, By End User.
The market for Blood Testing was dominated by North America.
Manufacturer and service provider, research institutes, universities, and private libraries, suppliers, and distributors.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Blood Testing Market Segmentation, Product and Service
8.1 Reagents & Kits
8.2 NAT Reagents & Kits
8.3 Other Reagents & Kits
8.4 ELISA Reagents & Kits
8.6 Outright Purchase
8.7 Rental Purchase
8.8 Software & Services
9. Blood Testing Market Segmentation, by Technology
9.1 Nucleic Acid Test
9.2 Real-time PCR
9.3 Transcription-mediated Amplification
9.5 Fluorescent Immunoassays
9.6 Chemiluminescent Immunoassays
9.7 Colorimetric Immunoassays
9.8 Rapid Tests
9.9 Next-generation Sequencing
9.10 Western Blot Assays
10. Blood Testing Market Segmentation, By End User
10.2 Blood Banks
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12. Company Profiles
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Bio-Rad Laboratories, Inc.
12.3 Trinity Biotech Plc
12.4 F. Hoffmann-La Roche AG
12.5 BioMerieux SA
12.6 Biomerica, Inc.
12.7 Quest Diagnostics
12.8 Danaher Corporation
12.9 Siemens Healthineers
12.11 Dickinson and Company
13. Competitive Landscape
13.1 Competitive Benchmark
13.2 Market Share analysis
13.3 Recent Developments